138 related articles for article (PubMed ID: 38684041)
21. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract][Full Text] [Related]
22. An extent of resection threshold for seizure freedom in patients with low-grade gliomas.
Xu DS; Awad AW; Mehalechko C; Wilson JR; Ashby LS; Coons SW; Sanai N
J Neurosurg; 2018 Apr; 128(4):1084-1090. PubMed ID: 28548599
[TBL] [Abstract][Full Text] [Related]
23. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
24. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
[TBL] [Abstract][Full Text] [Related]
25. The persistence of seizures after tumor resection negatively affects survival in low-grade glioma patients: a clinical retrospective study.
Mazzucchi E; Vollono C; Pauletto G; Lettieri C; Budai R; Gigli GL; Sabatino G; La Rocca G; Skrap M; Ius T
J Neurol; 2022 May; 269(5):2627-2633. PubMed ID: 34693462
[TBL] [Abstract][Full Text] [Related]
26. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
[TBL] [Abstract][Full Text] [Related]
27. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
[TBL] [Abstract][Full Text] [Related]
28. IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.
Zhong Z; Wang Z; Wang Y; You G; Jiang T
Epilepsy Res; 2015 Jan; 109():100-5. PubMed ID: 25524848
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Jain S; Gupta P; Shankar KB; Singh R; Siraj F
J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
[TBL] [Abstract][Full Text] [Related]
30. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
31. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
32. Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort.
Dao Trong P; Gluszak M; Reuss D; von Deimling A; Wick A; König L; Debus J; Herold-Mende C; Unterberg A; Jungk C
J Neurooncol; 2023 Feb; 161(3):605-615. PubMed ID: 36648586
[TBL] [Abstract][Full Text] [Related]
33. In vivo Metabolic Profiles as Determined by
Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
[TBL] [Abstract][Full Text] [Related]
34. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
[TBL] [Abstract][Full Text] [Related]
35. IDH1 mutation predicts seizure occurrence and prognosis in lower-grade glioma adults.
Tang T; Wang Y; Dai Y; Liu Q; Fan X; Cheng Y; Tang J; Xiao X; Shan Y; Wei P; Zhao G
Pathol Res Pract; 2024 Feb; 254():155165. PubMed ID: 38286053
[TBL] [Abstract][Full Text] [Related]
36. IDH1
Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
[TBL] [Abstract][Full Text] [Related]
37. Accelerated progression of IDH mutant glioma after first recurrence.
Miller JJ; Loebel F; Juratli TA; Tummala SS; Williams EA; Batchelor TT; Arrillaga-Romany I; Cahill DP
Neuro Oncol; 2019 May; 21(5):669-677. PubMed ID: 30668823
[TBL] [Abstract][Full Text] [Related]
38. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.
Choi J; Kim SH; Ahn SS; Choi HJ; Yoon HI; Cho JH; Roh TH; Kang SG; Chang JH; Suh CO
Sci Rep; 2020 Feb; 10(1):2086. PubMed ID: 32034238
[TBL] [Abstract][Full Text] [Related]
39. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
40. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H
J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
